The chemokine CCL2, also known as monocyte chemotactic protein-1 (MCP-1), stimulates leukocyte chemotaxis to sites of inflammation via signaling through the MCP-1 receptor, CCR2. RS 102895 is a spiropiperidine compound that acts as a CCR2 antagonist (IC50 = 0.36 μM). It inhibits the related CCR1 receptor with an IC50 value of 17.8 μM and inhibits adrenergic α1a, α1d, and 5HT1A receptors with IC50 values of 0.13, 0.32, and 47 μM, respectively. RS 102895 prevents chemotaxis of THP-1 cells (IC50 = 1.7 μM) when MCP-1 is presented as a chemoattractant.
